# "Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"

> **NCT05874505** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 60 (estimated)

## Conditions studied

- Behcet's Uveitis

## Interventions

- **DRUG:** Adalimumab
- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05874505
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-07
- **Primary completion:** 2026-11
- **Final completion:** 2027-07
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05874505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05874505, ""Comparison of the Efficacy and Safety of Adalimumab to That of Tocilizumab in Severe Uveitis of Behçet's Disease"". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05874505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*